Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901105 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
A Phase 3 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 205
- Enrollment target
NCT03901105 is a Phase 3 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 205 participants.
The verdict
NCT03901105, a Phase 3 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 205 participants
- Enrollment target
Study Summary
This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, lanabecestat, Eli Lilly and Company sponsor).
Interventions
- PROCEDURE Brain PET Scan
- DRUG flortaucipir F18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2019-04-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03901105
The ClinicalTrials.gov registry entry for NCT03901105 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brain PET Scan is the first listed.
NCT03901105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03901105 about?
NCT03901105 is a clinical study titled "Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease". This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previo...
What is the current status of trial NCT03901105?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2019-03-28. Estimated completion is 2019-04-28.
What interventions are being tested in trial NCT03901105?
The interventions under investigation include: Brain PET Scan (PROCEDURE), flortaucipir F18 (DRUG).
Who is sponsoring clinical trial NCT03901105?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.